{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:19:45Z","timestamp":1786371585637,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Acquired resistance to thyroid hormone appears to exist in the general population. We aimed to evaluate the association between indices of thyroid hormone sensitivity and non-alcoholic fatty liver disease (NAFLD), and made stratified analyses by diabetic status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 26,413 participants from a health screening program and 8,246 hospitalized patients with type 2 diabetes. Thyroid Feedback Quantile-based Index (TFQI), thyroid stimulating hormone index (TSHI) and thyrotroph thyroxine resistance index (TT4RI) were calculated. Advanced fibrosis risk was determined using the FIB-4 score. Multivariate logistic regression analysis was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>TFQI was associated with an increased risk of NAFLD in patients with diabetes (fourth quartile vs. first quartile: odds ratio [OR]=1.39 and 1.82 in hospitalized and non-hospitalized patients, respectively, both P&amp;lt;0.001) but not non-diabetic participants (OR=0.94, P=0.40). Further adjustment for the homeostasis model assessment of insulin resistance generated similar findings in diabetes (OR=1.27, P=0.025). The TFQI-associated NAFLD risk increase in diabetic patients was confined to NAFLD with low probability of advanced fibrosis (OR 1.42, P=0.001), but not those with intermediate-to-high probability (OR=0.86, P=0.23). Also, TFQI was associated with a significantly lower risk for advanced fibrosis in the diabetic at-risk patients (OR=0.62, P=0.005) but not those non-diabetic at-risk participants, independent of the presence of NAFLD. The association was less significant for TT4RI and TSHI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Impaired sensitivity to thyroid hormone was associated with an increased risk of developing NAFLD but a reduced risk of advanced fibrosis limited to diabetic individuals. Our findings suggest stratified studies of NAFLD based on diabetic status are needed in the future.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1450049","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:10:13Z","timestamp":1734498613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impaired sensitivity to thyroid hormone is associated with developing non-alcoholic fatty liver disease in euthyroid diabetic subjects"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaowen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.024","article-title":"Asian perspective on NAFLD-associated HCC","volume":"76","author":"Yip","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/apha.2016.217.issue-3","article-title":"Emerging role of thyroid hormone metabolites","volume":"217","author":"Gnocchi","year":"2016","journal-title":"Acta Physiol (Oxf)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0257","article-title":"Association between primary hypothyroidism and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"28","author":"Mantovani","year":"2018","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132907","article-title":"TSH levels as an independent risk factor for NAFLD and liver fibrosis in the general population","volume":"10","author":"Martinez-Escude","year":"2021","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0150","article-title":"Fatty liver largely explains associations of subclinical hypothyroidism with insulin resistance, metabolic syndrome, and subclinical coronary atherosclerosis","volume":"171","author":"Posadas-Romero","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/gerona\/glab037","article-title":"High-normal thyroid function predicts incident nonalcoholic fatty liver disease among middle-aged and older euthyroid subjects","volume":"77","author":"Gu","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1410","article-title":"Impaired sensitivity to thyroid hormones is associated with diabetes and metabolic syndrome","volume":"42","author":"Laclaustra","year":"2019","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab646","article-title":"Reduced sensitivity to thyroid hormone is associated with diabetes and hypertension","volume":"107","author":"Mehran","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0500","article-title":"Impaired sensitivity to thyroid hormones is associated with hyperuricemia, obesity, and cardiovascular disease risk in subjects with subclinical hypothyroidism","volume":"32","author":"Sun","year":"2022","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1530\/EJE-21-0640","article-title":"Thyroid hormone resistance index and mortality in euthyroid subjects: Di@bet.es study","volume":"186","author":"Alonso","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.766419","article-title":"Sensitivity to thyroid hormone indices are closely associated with NAFLD","volume":"12","author":"Lai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6512.13","article-title":"Ultrasound scanning in the detection of hepatic fibrosis and steatosis","volume":"292","author":"Saverymuttu","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Ortiga-Carvalho","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103034","DOI":"10.1016\/j.dsx.2024.103034","article-title":"Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom","volume":"18","author":"Kuchay","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.20517\/2394-5079.2021.82","article-title":"The roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD","volume":"7","author":"Zhou","year":"2021","journal-title":"Hepatoma Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00475","article-title":"Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD","volume":"103","author":"Bruinstroop","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi","year":"2020","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165927","article-title":"Hypothyroidism-induced nonalcoholic fatty liver disease (HIN): mechanisms and emerging therapeutic options","volume":"21","author":"Tanase","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12070582","article-title":"3,5-T2-an endogenous thyroid hormone metabolite as promising lead substance in anti-steatotic drug development","volume":"12","author":"Sane","year":"2022","journal-title":"Metabolites"},{"key":"B28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0533","article-title":"Thyroid-stimulating hormone and thyroid hormones and incidence of diabetes: prospective results of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"32","author":"Birck","year":"2022","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12916-021-02121-2","article-title":"Association between thyroid dysfunction and type 2 diabetes: a meta-analysis of prospective observational studies","volume":"19","author":"Rong","year":"2021","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi","year":"2019","journal-title":"Endocr Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2174\/1389557523666230314113543","article-title":"Levothyroxine and non-alcoholic fatty liver disease: A mini review","volume":"24","author":"Singha","year":"2024","journal-title":"Mini Rev Med Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1718","article-title":"Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects","volume":"92","author":"Roos","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.024","article-title":"Low-normal thyroid function is associated with advanced fibrosis among adults in the United States","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.2713","article-title":"Models of non-alcoholic fatty liver disease and potential translational value: the effects of 3,5-L-diiodothyronine","volume":"16","author":"Grasselli","year":"2017","journal-title":"Ann Hepatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/15332640.2018.1456388","article-title":"Correlates of alcohol consumption and alcohol dependence among older adults in contemporary China: Results from the Chinese Longitudinal Healthy Longevity Survey","volume":"19","author":"Lee","year":"2020","journal-title":"J Ethn Subst Abuse"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1450049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:10:19Z","timestamp":1734498619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1450049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":39,"alternative-id":["10.3389\/fendo.2024.1450049"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1450049","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"article-number":"1450049"}}